EcoDrugPlus

Nicastrin

Ensembl ID : ENSAPEG00000020471
Gene Symbol: NCSTN
2 Cross references
204 Possible Orthologues:

Nicotinamide Phosphoribosyltransferase

Ensembl ID : ENSAPEG00000018310
Gene Symbol: NAMPT
1 Cross references
219 Possible Orthologues:

Notch Receptor 1b

Ensembl ID : ENSAPEG00000009619
Gene Symbol: NOTCH1B
1 Cross references
200 Possible Orthologues:

Notch Receptor 3

Ensembl ID : ENSAPEG00000010014
Gene Symbol: NOTCH3
1 Cross references
194 Possible Orthologues:

Nuclear Factor Kappa B Subunit 1

Ensembl ID : ENSAPEG00000004000
Gene Symbol: NFKB1
1 Cross references
202 Possible Orthologues:

Nuclear Receptor Subfamily 1, Group H, Member 3

Ensembl ID : ENSAPEG00000000099
Gene Symbol: NR1H3
1 Cross references
392 Possible Orthologues:

Nuclear Receptor Subfamily 1, Group H, Member 4

Ensembl ID : ENSAPEG00000007163
Gene Symbol: NR1H4
1 Cross references
388 Possible Orthologues:

Nuclear Receptor Subfamily 3 Group C Member 1

Ensembl ID : ENSAPEG00000017923
Gene Symbol: NR3C1
2 Cross references
206 Possible Orthologues:

Nuclear Receptor Subfamily 3, Group C, Member 1 (Glucocorticoid Receptor)

Ensembl ID : ENSAPEG00000018955
Gene Symbol: NR3C1
1 Cross references
207 Possible Orthologues:

Nuclear Receptor Subfamily 3, Group C, Member 2

Ensembl ID : ENSAPEG00000023891
Gene Symbol: NR3C2
1 Cross references
209 Possible Orthologues:

Nucleotide-Binding Oligomerization Domain Containing 2

Ensembl ID : ENSAPEG00000010272
Gene Symbol: NOD2
1 Cross references
167 Possible Orthologues:

Opiate Receptor-Like 1

Ensembl ID : ENSAPEG00000004527
Gene Symbol: OPRL1
1 Cross references
190 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).